Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 139 articles: HTML format

Single Articles

July 2026
1. WEI T, Zhong G, Qian J, Wang J, et al
   Metabolic-epigenetic regulation of TRPM3 via H3K18 lactylation in dorsal root ganglia mediates bone cancer pain and its attenuation by microwave ablation.
   Cancer Lett. 2026;649:218505.
   PubMed     Abstract available
   
   
   June 2026
2. ZHOU Y, Zang R, Li Z, Zhang Z, et al
   Decoding the SHOX2 methylation-expression paradox in lung adenocarcinoma: Dual-regulatory methylation patterns drive oncogenic activation and prognostic relevance.
   Cancer Lett. 2026;648:218456.
   PubMed     Abstract available
   
   
   
3. HINZ TK, Le AT, Doan T, Ast A, et al
   Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.
   Cancer Lett. 2026;648:218467.
   PubMed     Abstract available
   
   
   
4. ZHANG Z, Yang X, Zheng R, Zang Y, et al
   Postoperative exosomal miR-1246 fuels hepatocellular carcinoma metastasis via BMP9-SMAD7 axis suppression.
   Cancer Lett. 2026;648:218469.
   PubMed     Abstract available
   
   
   
5. YANG L, Yang H, Zhao M, Wen Y, et al
   IGHG1(+) malignant epithelial Cell-myCAF crosstalk via MIF-CD74/APP-CD74 drives early brain metastasis in NSCLC: Delineated via primary tumor-brain metastasis single-cell and spatial transcriptomics.
   Cancer Lett. 2026;647:218451.
   PubMed     Abstract available
   
   
   May 2026
6. WU H, Zhang J, Yu Y, Wang W, et al
   BRIP1-mediated RINT1 acetylation and NF-kappaB activation promote DNA repair and immunosuppressive microenvironment in lung adenocarcinoma.
   Cancer Lett. 2026;645:218357.
   PubMed     Abstract available
   
   
   April 2026
7. LIANG S, Wang Q, Zhang M, Song X, et al
   A tumor-derived mitochondrial tsRNA drives vascular invasion of lung adenocarcinoma by promoting ribosomal assembly in endothelial cells.
   Cancer Lett. 2026;644:218324.
   PubMed     Abstract available
   
   
   
8. LIU L, Wu Q, Fang S, Hu Z, et al
   Organoid-based modeling unveils Dnmt3a-driven epigenetic regulation of phenotypic plasticity in small cell lung cancer.
   Cancer Lett. 2026 Apr 16:218516. doi: 10.1016/j.canlet.2026.218516.
   PubMed     Abstract available
   
   
   
9. ARBEL R, Rokach L, Razi T, Tadmor T, et al
   Validation of "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade" in an independent cohort of 4,407 patients.
   Cancer Lett. 2026;643:218319.
   PubMed     Abstract available
   
   
   
10. YANG J, Yu H, Zhong C, Xu L, et al
    Liver cancer-derived exosomal PTK6 induces the secretion of pulmonary CHI3L1 to facilitate lung metastatic niche formation.
    Cancer Lett. 2026;643:218312.
    PubMed     Abstract available
    
    
    
11. WANG H, Tian X, Zhu W, Wang Y, et al
    ZBTB20 promotes malignancy and stemness in lung squamous cell carcinoma through the transcriptional repression of KCTD1 and activation of Hedgehog signaling.
    Cancer Lett. 2026;643:218301.
    PubMed     Abstract available
    
    
    
12. LIU D, Liu B, Yang R, Song J, et al
    Targeting Galectin-9 to overcome immunosuppression and potentiate ATR inhibitor therapy.
    Cancer Lett. 2026;643:218283.
    PubMed     Abstract available
    
    
    
13. LEU JS, Deng H, Tran HN, Wei X, et al
    Combined inhibition of S100A4 and TIGIT suppresses late-stage breast cancer metastasis.
    Cancer Lett. 2026;649:218491.
    PubMed     Abstract available
    
    
    March 2026
14. YANG Y, Liu C, Yang L, Zheng S, et al
    IL-6 drives chemoimmunotherapy resistance in NSCLC by reprogramming myeloid cells and impairing cytotoxic lymphocyte function.
    Cancer Lett. 2026;641:218259.
    PubMed     Abstract available
    
    
    
15. EL-GAZZAR A, Aschenbrenner B, Forsthuber A, Kramer M, et al
    Targeting P2RY2 reprograms tumor immunity and inhibits tumor growth in non-small cell lung cancer.
    Cancer Lett. 2026 Mar 24:218448. doi: 10.1016/j.canlet.2026.218448.
    PubMed     Abstract available
    
    
    
16. FABRIZIO FP, Pegreffi F, Leonardi R, Mazza M, et al
    Can Macrophages Predict Response to Neoadjuvant Therapy in Lung Cancer? A Lesson from Breast Cancer.
    Cancer Lett. 2026 Mar 17:218438. doi: 10.1016/j.canlet.2026.218438.
    PubMed    
    
    
    February 2026
17. DONG X, Li R, Yao X, Li Y, et al
    Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions.
    Cancer Lett. 2026;639:218203.
    PubMed     Abstract available
    
    
    
18. APPADURAI MI, Alsafwani ZW, Chaudhary S, Shah A, et al
    Ixazomib triggers autophagic degradation of MUC5AC/integrin-beta4 and inhibits non-small cell lung cancer progression.
    Cancer Lett. 2026 Feb 28:218333. doi: 10.1016/j.canlet.2026.218333.
    PubMed     Abstract available
    
    
    
19. YAN JS, Wang YZ, Zhao SY, Na FJ, et al
    Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies.
    Cancer Lett. 2026;645:218382.
    PubMed     Abstract available
    
    
    
20. CHEN Y, Xing H, Yang X, Shen J, et al
    Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer.
    Cancer Lett. 2026;645:218356.
    PubMed     Abstract available
    
    
    
21. YANG J, Zhang M, Gao C, Yao X, et al
    The Histone-Modified Landscape: Core Mechanisms of Osimertinib Resistance in EGFR-Mutant Lung Cancer.
    Cancer Lett. 2026 Feb 19:218321. doi: 10.1016/j.canlet.2026.218321.
    PubMed     Abstract available
    
    
    
22. HU S, Zhao Z, Zhao J, Liang Y, et al
    Protein kinase Ciota-driven macrophage infiltration mediates immunosuppression in non-small cell lung cancer.
    Cancer Lett. 2026 Feb 18:218330. doi: 10.1016/j.canlet.2026.218330.
    PubMed     Abstract available
    
    
    
23. XU Z, Gao J, Ye C, Li Y, et al
    PPP4C restores YAP1 activity by modulating MST4 phosphorylation to enhance immunosuppression and augment tumor growth in non-small cell lung cancer.
    Cancer Lett. 2026 Feb 12:218306. doi: 10.1016/j.canlet.2026.218306.
    PubMed     Abstract available
    
    
    January 2026
24. SHEN A, Zheng S, Tang X, Yao Y, et al
    Integrated multi-omics analyses identified the H3K18la-based spatiotemporal characteristics and risk-stratified treatment strategy in lung adenocarcinoma.
    Cancer Lett. 2026;638:218158.
    PubMed     Abstract available
    
    
    
25. HUANG Y, Wei Z, Ye G, Cui Y, et al
    Automated CT-derived Body Composition Predicts Pathologic Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Cancer Lett. 2026 Jan 6:218229. doi: 10.1016/j.canlet.2025.218229.
    PubMed     Abstract available
    
    
    
26. LI Y, Li C, Wang Y, Zhou J, et al
    Mitigating tumor heterogeneity in lung Cancer: A dual-targeted NIR-II imaging strategy for accurate tumor localization and intraoperative navigation.
    Cancer Lett. 2026;640:218241.
    PubMed     Abstract available
    
    
    
27. WANG P, Tang HXL, Song J, Yang Y, et al
    Identification of a novel RET::FOXJ3 fusion in lung adenocarcinoma associated with lack of response to pralsetinib.
    Cancer Lett. 2026;636:218100.
    PubMed     Abstract available
    
    
    December 2025
28. MENG X, Bi N, Wang J, Meng X, et al
    Consensus on the Diagnosis and Treatment of Unresectable Stage III Driver Gene-Positive Non-Small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 17:218223. doi: 10.1016/j.canlet.2025.218223.
    PubMed     Abstract available
    
    
    
29. WU F, Shen J, Zhao Z, Chen Y, et al
    HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8(+) T cell glutamine metabolism via KIR3DL3 interaction.
    Cancer Lett. 2025;639:218219.
    PubMed     Abstract available
    
    
    
30. ZHANG WY, Wang ZQ, Fan XX
    Overcoming EGFR TKI Resistance and Immunosuppression in Non-Small Cell Lung Cancer via EGFR/TLR9/PD-L1 Triple-Targeted Therapy.
    Cancer Lett. 2025 Dec 10:218217. doi: 10.1016/j.canlet.2025.218217.
    PubMed    
    
    
    
31. GAO Y, Li LX, Rowland A, Karapetis CS, et al
    Progressive Lesion Type is Predictive of Post-progression Survival in First-line Chemoimmunotherapy for Non-small Cell Lung Cancer.
    Cancer Lett. 2025 Dec 10:218191. doi: 10.1016/j.canlet.2025.218191.
    PubMed    
    
    
    
32. HUANG X, Liang J, Yi Y, Zhu J, et al
    Targeting inosine metabolism to enhance EGFR-targeted therapy in lung adenocarcinoma.
    Cancer Lett. 2025;634:218069.
    PubMed     Abstract available
    
    
    
33. XIAO C, Fan T, Wang D, Yin H, et al
    RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy.
    Cancer Lett. 2025;634:218062.
    PubMed     Abstract available
    
    
    
34. KUANG Y, Yang S, Tian X, Cheng H, et al
    Hinokitiol preferentially suppresses metastatic lung adenocarcinoma via TMDD1-mediated ferroptosis induction and iron-sulfur cluster inhibition.
    Cancer Lett. 2025;634:218046.
    PubMed     Abstract available
    
    
    November 2025
35. SHE L, Chen J, Liu JY, Liu JS, et al
    A two-stage genome-wide association study to identify novel genetic loci associated with irAEs in lung cancer patients received PD-1/PD-L1 inhibitors.
    Cancer Lett. 2025 Nov 22:218168. doi: 10.1016/j.canlet.2025.218168.
    PubMed     Abstract available
    
    
    
36. KHAN MA, Khan P, Fatima M, Rehman AU, et al
    Targeting FOXM1 reshapes antitumor immunity to attenuate small cell lung cancer progression.
    Cancer Lett. 2025;638:218160.
    PubMed     Abstract available
    
    
    
37. LIU Y, Prasad CB, Qiu Z, Singh D, et al
    CD40 drives tumor growth in non-small cell lung cancer via non-canonical immune-independent mechanisms.
    Cancer Lett. 2025;637:218151.
    PubMed    
    
    
    
38. WANG G, Wang W
    Letter to the editor on 'AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study'.
    Cancer Lett. 2025;636:218107.
    PubMed    
    
    
    October 2025
39. XU Y, Chen M, Gao X, Liu X, et al
    Efficacy and safety of sunvozertinib monotherapy as first-line treatment in NSCLC patients with EGFR exon 20 insertion mutations: A phase 2, single-center trial.
    Cancer Lett. 2025;630:217904.
    PubMed     Abstract available
    
    
    
40. ZADRA I, Abad E, Krasko A, Porqueras VC, et al
    A novel mismatch repair deficient lung adenocarcinoma model for immunotherapy research.
    Cancer Lett. 2025;629:217882.
    PubMed     Abstract available
    
    
    September 2025
41. JIA W, Ma L, Bai M, Li J, et al
    Loss of ADAR1 in lung cancer activates anti-tumour immunity and suppresses tumour cell growth via the RIG-I/MDA5-MAVS pathway.
    Cancer Lett. 2025 Sep 30:218071. doi: 10.1016/j.canlet.2025.218071.
    PubMed     Abstract available
    
    
    
42. LI X, Liu K, Zhang Z, Zhu W, et al
    Targeting the cholinergic-astrocyte axis: A novel strategy for brain metastasis prevention in lung adenocarcinoma.
    Cancer Lett. 2025;628:217870.
    PubMed     Abstract available
    
    
    
43. CHEN Y, Wang X, Li H, Zhang Z, et al
    Oncoprotein SND1-enriched exosomes facilitate melanoma lung metastasis by regulating CD47-SIRPalpha-mediated macrophage reprogramming.
    Cancer Lett. 2025 Sep 25:218037. doi: 10.1016/j.canlet.2025.218037.
    PubMed     Abstract available
    
    
    
44. JIANG C, He X, Chen X, Huang J, et al
    Lactate accumulation drives hepatocellular carcinoma metastasis through facilitating tumor-derived exosome biogenesis by Rab7A lactylation.
    Cancer Lett. 2025;627:217636.
    PubMed     Abstract available
    
    
    August 2025
45. CHEN Z, Vallega KA, Wang D, Bildtsen E, et al
    Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.
    Cancer Lett. 2025;633:218010.
    PubMed     Abstract available
    
    
    
46. YANG Y, Li Z, Yu X, Zheng Y, et al
    WDR11-DT enhances radiosensitivity via promoting PARP1 degradation and homologous recombination deficiency.
    Cancer Lett. 2025;625:217757.
    PubMed     Abstract available
    
    
    July 2025
47. MA G, Wang D, Deng Y, Huang W, et al
    Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib.
    Cancer Lett. 2025;632:217962.
    PubMed     Abstract available
    
    
    
48. LUCA AC, Kurnaeva M, John DK, Machtinger M, et al
    Loss of SPHK1 fuels inflammation to drive KRAS-mutated lung adenocarcinoma.
    Cancer Lett. 2025;623:217733.
    PubMed     Abstract available
    
    
    
49. JIANG M, Zhang K, Wei G, Qi F, et al
    HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD.
    Cancer Lett. 2025;623:217716.
    PubMed     Abstract available
    
    
    June 2025
50. HUANG Y, Song J, Chen J, Li F, et al
    The significance of protein N-glycosylation in the pathogenesis of lung cancer and its clinical implications.
    Cancer Lett. 2025 Jun 25:217849. doi: 10.1016/j.canlet.2025.217849.
    PubMed     Abstract available
    
    
    
51. CHEN H, Yu G, Lin H, Zhou XA, et al
    Loss of FTSJ3 promotes R-loop-associated DNA damage and facilitates chemosensitivity in lung cancer cells.
    Cancer Lett. 2025 Jun 13:217877. doi: 10.1016/j.canlet.2025.217877.
    PubMed     Abstract available
    
    
    
52. KHORRAMI M, Mutha P, Barrera C, Viswanathan VS, et al
    AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study.
    Cancer Lett. 2025;628:217872.
    PubMed     Abstract available
    
    
    May 2025
53. WADE WEI TY, Hsia JY, Yang TY, Huang YX, et al
    Mechanistic Insights into CLNS1A-Mediated Chemoresistance and Tumor Progression in Non-small Cell Lung Cancer.
    Cancer Lett. 2025 May 7:217783. doi: 10.1016/j.canlet.2025.217783.
    PubMed     Abstract available
    
    
    April 2025
54. JIANG J, Chen H, Zhao C, Li T, et al
    PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinoma.
    Cancer Lett. 2025;616:217584.
    PubMed     Abstract available
    
    
    
55. LIN H, Hua J, Gong Z, Chen M, et al
    Multimodal radiopathological integration for prognosis and prediction of adjuvant chemotherapy benefit in resectable lung adenocarcinoma: A multicentre study.
    Cancer Lett. 2025;616:217557.
    PubMed     Abstract available
    
    
    
56. MO Y, Qin Y, Li P, Wu M, et al
    Thyroxine alleviates interstitial lung disease induced by combined radiotherapy and immunotherapy.
    Cancer Lett. 2025;615:217504.
    PubMed     Abstract available
    
    
    
57. XIAO X, Huang L, Li M, Zhang Q, et al
    Intersection between lung cancer and neuroscience: opportunities and challenges.
    Cancer Lett. 2025 Apr 5:217701. doi: 10.1016/j.canlet.2025.217701.
    PubMed     Abstract available
    
    
    March 2025
58. PENG X, Yang R, Wang C, Peng W, et al
    The YTHDF3-DT/miR-301a-3p /INHBA axis attenuates autophagy-dependent ferroptosis in lung adenocarcinoma.
    Cancer Lett. 2025;613:217503.
    PubMed     Abstract available
    
    
    
59. LI J, Xu S, Zhan Y, Lv X, et al
    CircRUNX1 enhances the Warburg effect and immune evasion in non-small cell lung cancer through the miR-145/HK2 pathway.
    Cancer Lett. 2025 Mar 14:217639. doi: 10.1016/j.canlet.2025.217639.
    PubMed     Abstract available
    
    
    
60. ZHAO L, Ren Y, Gong C, Xiong S, et al
    RMethyMD: An integrated platform for exploring RNA methylation in pan-cancer via a multiomics analysis.
    Cancer Lett. 2025;612:217462.
    PubMed     Abstract available
    
    
    
61. TANG X, Hu J, Guo R, Wang Y, et al
    RET-AREAL: A multi-center, real-world data analysis on the efficacy of pralsetinib in acquired RET fusion after resistance to EGFR/ALK-TKIs.
    Cancer Lett. 2025;612:217455.
    PubMed     Abstract available
    
    
    February 2025
62. FU R, Zhang C, Song MM, Gao X, et al
    A single-cell map of patients with non-small cell lung cancer harboring rare-driver mutations after anti-PD-1 treatment.
    Cancer Lett. 2025;616:217595.
    PubMed     Abstract available
    
    
    January 2025
63. HUANG M, Sun J, Jiang Q, Zhao X, et al
    CircKIAA0182-YBX1 Axis: A Key Driver of Lung Cancer Progression and Chemoresistance.
    Cancer Lett. 2025;612:217494.
    PubMed     Abstract available
    
    
    December 2024
64. YU JJ, Zhou DD, Cui B, Zhang C, et al
    Corrigendum to <[ Cancer Letters 474 (2020) 23-35]>.
    Cancer Lett. 2024 Dec 30:217434. doi: 10.1016/j.canlet.2024.217434.
    PubMed    
    
    
    
65. DONG XD, Zhang M, Teng QX, Lei ZN, et al
    Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies.
    Cancer Lett. 2024;607:217309.
    PubMed     Abstract available
    
    
    
66. HUANG S, Chung JY, Li C, Wu Y, et al
    Corrigendum to "Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma" [Cancer Lett. 604 (2024) 217272].
    Cancer Lett. 2024 Dec 27:217425. doi: 10.1016/j.canlet.2024.217425.
    PubMed    
    
    
    
67. YAMAMOTO G, Tanaka K, Kamata R, Saito H, et al
    WEE1 Confers Resistance to KRAS(G12C) Inhibitors in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Dec 24:217414. doi: 10.1016/j.canlet.2024.217414.
    PubMed     Abstract available
    
    
    
68. SUAY G, Garcia-Canaveras JC, Aparisi F, Garcia J, et al
    Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.
    Cancer Lett. 2024;606:217317.
    PubMed     Abstract available
    
    
    
69. NERLAKANTI N, McGuire JJ, Bishop RT, Nasr MM, et al
    Histone deacetylase upregulation of neuropilin-1 in osteosarcoma is essential for pulmonary metastasis.
    Cancer Lett. 2024;606:217302.
    PubMed     Abstract available
    
    
    November 2024
70. LI J, Wang X, Cao G, Wu Y, et al
    CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models.
    Cancer Lett. 2024;605:217305.
    PubMed     Abstract available
    
    
    
71. ZHAO Y, Zhang D, Meng B, Zhang Y, et al
    Integrated proteomic and glycoproteomic analysis reveals heterogeneity and molecular signatures of brain metastases from lung adenocarcinomas.
    Cancer Lett. 2024;605:217262.
    PubMed     Abstract available
    
    
    
72. GE H, Malsiu F, Gao Y, Losmanova T, et al
    Inhibition of LDHB suppresses the metastatic potential of lung cancer by reducing mitochondrial GSH catabolism.
    Cancer Lett. 2024 Nov 28:217353. doi: 10.1016/j.canlet.2024.217353.
    PubMed     Abstract available
    
    
    
73. ZHANG J, Wu Q, Zhu L, Xie S, et al
    Corrigendum to "SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer" [Cancer Lett. 524 (2022) 268-283].
    Cancer Lett. 2024 Nov 23:217337. doi: 10.1016/j.canlet.2024.217337.
    PubMed    
    
    
    October 2024
74. PLAUGHER DR, Childress AR, Gosser CM, Esoe DP, et al
    Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer.
    Cancer Lett. 2024 Oct 4:217281. doi: 10.1016/j.canlet.2024.217281.
    PubMed     Abstract available
    
    
    
75. WU J, Chen Y, Zou H, Xu K, et al
    6-Phosphogluconate dehydrogenase promotes glycolysis and fatty acid synthesis by inhibiting the AMPK pathway in lung adenocarcinoma cells.
    Cancer Lett. 2024;601:217177.
    PubMed     Abstract available
    
    
    September 2024
76. HUANG L, Liu X, Chen Q, Yang J, et al
    TGF-beta-induced lncRNA TBUR1 promotes EMT and metastasis in lung adenocarcinoma via hnRNPC-mediated GRB2 mRNA stabilization.
    Cancer Lett. 2024;600:217153.
    PubMed     Abstract available
    
    
    
77. WU J, Zhao Q, Chen S, Xu H, et al
    NSUN4-mediated m5C modification of circERI3 promotes lung cancer development by altering mitochondrial energy metabolism.
    Cancer Lett. 2024 Sep 25:217266. doi: 10.1016/j.canlet.2024.217266.
    PubMed     Abstract available
    
    
    
78. HUANG S, Yat-Fai Chung J, Li C, Wu Y, et al
    Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma.
    Cancer Lett. 2024 Sep 24:217272. doi: 10.1016/j.canlet.2024.217272.
    PubMed     Abstract available
    
    
    
79. GARGALIONIS AN, Papavassiliou KA, Basdra EK, Papavassiliou AG, et al
    Exploiting tumor mechanomedicine for lung cancer treatment.
    Cancer Lett. 2024;604:217229.
    PubMed    
    
    
    
80. GANG X, Yan J, Li X, Shi S, et al
    Immune Checkpoint Inhibitors Rechallenge in Non-Small Cell Lung Cancer: Current Evidence and Future Directions.
    Cancer Lett. 2024 Sep 9:217241. doi: 10.1016/j.canlet.2024.217241.
    PubMed     Abstract available
    
    
    
81. LA VECCHIA S, Fontana S, Salaroglio IC, Anobile DP, et al
    Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy.
    Cancer Lett. 2024;604:217221.
    PubMed     Abstract available
    
    
    
82. WEI X, Uchibori K, Kondo N, Utsumi T, et al
    MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
    Cancer Lett. 2024 Sep 5:217220. doi: 10.1016/j.canlet.2024.217220.
    PubMed     Abstract available
    
    
    
83. SUN SY
    Is tumor microenvironment important for targeted therapy in lung cancer?
    Cancer Lett. 2024 Sep 3:217203. doi: 10.1016/j.canlet.2024.217203.
    PubMed    
    
    
    
84. XUE R, Li X, Yang L, Yang M, et al
    Evaluation and integration of cell-free DNA signatures for detection of lung cancer.
    Cancer Lett. 2024 Sep 2:217216. doi: 10.1016/j.canlet.2024.217216.
    PubMed     Abstract available
    
    
    August 2024
85. LI J, Bai M, Jia W, Zhai X, et al
    Irradiated tumor cell-released microparticles enhance the therapeutic efficacy of PD-1 inhibitors by promoting M1-TAMs polarization in NSCLC brain metastases.
    Cancer Lett. 2024;598:217133.
    PubMed     Abstract available
    
    
    
86. LU Y, Sun Y, Zhang J, Kong M, et al
    The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants.
    Cancer Lett. 2024;596:217020.
    PubMed     Abstract available
    
    
    
87. FLETCHER K, Cortellini A, Ganta T, Kankaria R, et al
    Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
    Cancer Lett. 2024;596:217001.
    PubMed     Abstract available
    
    
    
88. KIM YJ, Lee M, Kim EH, Lee S, et al
    Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study.
    Cancer Lett. 2024;596:216998.
    PubMed     Abstract available
    
    
    
89. CHOW Z, Johnson J, Chauhan A, Jeong JC, et al
    Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Cancer Lett. 2024;596:216993.
    PubMed     Abstract available
    
    
    July 2024
90. HUANG L, Wang J, Wang X, Zheng S, et al
    Sulforaphane suppresses bladder cancer metastasis via blocking actin nucleation-mediated pseudopodia formation.
    Cancer Lett. 2024 Jul 29:217145. doi: 10.1016/j.canlet.2024.217145.
    PubMed     Abstract available
    
    
    
91. LIU M, Gu L, Zhang Y, Li Y, et al
    LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma.
    Cancer Lett. 2024;595:217025.
    PubMed     Abstract available
    
    
    
92. NAKAMURA R, Yamada T, Tokuda S, Morimoto K, et al
    Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Cancer Lett. 2024;598:217124.
    PubMed     Abstract available
    
    
    
93. SINGH D, Qiu Z, Jonathan SM, Fa P, et al
    PP2A B55alpha Inhibits Epithelial-Mesenchymal Transition Via Regulation of Slug Expression in Non-Small Cell Lung Cancer.
    Cancer Lett. 2024 Jul 8:217110. doi: 10.1016/j.canlet.2024.217110.
    PubMed     Abstract available
    
    
    
94. LI X, Shang S, Wu M, Song Q, et al
    Gut microbial metabolites in lung cancer development and immunotherapy: Novel insights into gut-lung axis.
    Cancer Lett. 2024;598:217096.
    PubMed     Abstract available
    
    
    
95. SHU M, Huang L, Chen Y, Wang Y, et al
    Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma.
    Cancer Lett. 2024;593:216835.
    PubMed     Abstract available
    
    
    June 2024
96. GUGNONI M, Lorenzini E, Torricelli F, Donati B, et al
    Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma.
    Cancer Lett. 2024;592:216950.
    PubMed     Abstract available
    
    
    
97. HE Q, Qu M, Xu C, Wu L, et al
    Smoking-induced CCNA2 expression promotes lung adenocarcinoma tumorigenesis by boosting AT2/AT2-like cell differentiation.
    Cancer Lett. 2024;592:216922.
    PubMed     Abstract available
    
    
    
98. XU Z, Shi Y, Zhu L, Luo J, et al
    Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.
    Cancer Lett. 2024 Jun 21:217075. doi: 10.1016/j.canlet.2024.217075.
    PubMed     Abstract available
    
    
    
99. GUO W, Qiao T, Li H, Zhao Y, et al
    Peripheral CD8(+)PD-1(+) T cells as novel biomarker for neoadjuvant chemoimmunotherapy in humanized mice of non-small cell lung cancer.
    Cancer Lett. 2024;597:217073.
    PubMed     Abstract available
    
    
    
100. LIU X, Zheng W, Zhang L, Cao Z, et al
     Corrigendum to "Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation" [Cancer Lett. 586 (2024) 216707/CAN_216707].
     Cancer Lett. 2024 Jun 5:217003. doi: 10.1016/j.canlet.2024.217003.
     PubMed    
     
     
     
101. ZHENG L, Shen J, Chen Y, Lin J, et al
     FBXO43 promotes cell cycle progression in cancer cells through stabilizing SKP2.
     Cancer Lett. 2024;591:216848.
     PubMed     Abstract available
     
     
     May 2024
102. ZHANG L, Xu Y, Cheng Z, Zhao J, et al
     The EGR1/miR-139/NRF2 axis orchestrates radiosensitivity of non-small-cell lung cancer via ferroptosis.
     Cancer Lett. 2024;595:217000.
     PubMed     Abstract available
     
     
     
103. BOSSE Y, Dasgupta A, Abadier M, Guthrie V, et al
     Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
     Cancer Lett. 2024;594:216984.
     PubMed     Abstract available
     
     
     
104. JIANG Y, Li S, Ramesh R
     Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.
     Cancer Lett. 2024 May 10:216932. doi: 10.1016/j.canlet.2024.216932.
     PubMed    
     
     
     
105. CHEN X, Yuan M, Zhong T, Wang M, et al
     LILRB2 Inhibition Enhances Radiation Sensitivity in Non-Small Cell Lung Cancer by Attenuating Radiation-Induced Senescence.
     Cancer Lett. 2024 May 3:216930. doi: 10.1016/j.canlet.2024.216930.
     PubMed     Abstract available
     
     
     
106. WANG PS, Liu Z, Sweef O, Saeed AF, et al
     Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis.
     Cancer Lett. 2024;589:216827.
     PubMed     Abstract available
     
     
     
107. YU T, Liu Z, Tao Q, Xu X, et al
     Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming.
     Cancer Lett. 2024;589:216824.
     PubMed     Abstract available
     
     
     
108. LUO S, Luo Y, Wang Z, Yin H, et al
     Super-enhancer mediated upregulation of MYEOV suppresses ferroptosis in lung adenocarcinoma.
     Cancer Lett. 2024;589:216811.
     PubMed     Abstract available
     
     
     April 2024
109. SUN BB, Wang GZ, Han SC, Yang FY, et al
     Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer.
     Cancer Lett. 2024 Apr 30:216929. doi: 10.1016/j.canlet.2024.216929.
     PubMed     Abstract available
     
     
     
110. YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al
     Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
     Cancer Lett. 2024;588:216816.
     PubMed     Abstract available
     
     
     
111. MOON JW, Hong BJ, Kim SK, Park MS, et al
     Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
     Cancer Lett. 2024;588:216781.
     PubMed     Abstract available
     
     
     
112. LUO J, Cheng K, Ji X, Gao C, et al
     Anlotinib enhanced CD8(+) T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer.
     Cancer Lett. 2024;591:216892.
     PubMed     Abstract available
     
     
     
113. MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
     AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
     Cancer Lett. 2024;587:216692.
     PubMed     Abstract available
     
     
     
114. GAO GB, Chen L, Pan JF, Lei T, et al
     LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
     Cancer Lett. 2024 Apr 2:216826. doi: 10.1016/j.canlet.2024.216826.
     PubMed     Abstract available
     
     
     
115. HAO Z, Xin Z, Chen Y, Shao Z, et al
     JAML promotes the antitumor role of tumor-resident CD8(+) T cells by facilitating their innate-like function in human lung cancer.
     Cancer Lett. 2024 Apr 1:216839. doi: 10.1016/j.canlet.2024.216839.
     PubMed     Abstract available
     
     
     March 2024
116. ZHANG E, Sun Q, Zhang C, Ma H, et al
     Comprehensive functional interrogation of susceptibility loci in GWASs identified KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
     Cancer Lett. 2024;585:216646.
     PubMed     Abstract available
     
     
     
117. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
     Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
     Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
     PubMed     Abstract available
     
     
     
118. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
     Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
     Cancer Lett. 2024;584:216608.
     PubMed     Abstract available
     
     
     February 2024
119. HAN R, Lin C, Lu C, Wang Y, et al
     Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
     Cancer Lett. 2024;588:216762.
     PubMed     Abstract available
     
     
     
120. LIU X, Zheng W, Zhang L, Cao Z, et al
     Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation.
     Cancer Lett. 2024 Feb 6:216707. doi: 10.1016/j.canlet.2024.216707.
     PubMed     Abstract available
     
     
     
121. LU X, Yu R, Li Z, Yang M, et al
     JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
     Cancer Lett. 2024;582:216517.
     PubMed     Abstract available
     
     
     
122. LIN S, He C, Song L, Sun L, et al
     Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma.
     Cancer Lett. 2024;582:216588.
     PubMed     Abstract available
     
     
     
123. BISWAS U, Roy R, Ghosh S, Chakrabarti G, et al
     The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
     Cancer Lett. 2024 Feb 1:216662. doi: 10.1016/j.canlet.2024.216662.
     PubMed     Abstract available
     
     
     January 2024
124. SUN J, Dong M, Xiang X, Zhang S, et al
     Notch signaling and targeted therapy in non-small cell lung cancer.
     Cancer Lett. 2024 Jan 30:216647. doi: 10.1016/j.canlet.2024.216647.
     PubMed     Abstract available
     
     
     
125. SUI Q, Hu Z, Liang J, Lu T, et al
     Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.
     Cancer Lett. 2024;581:216497.
     PubMed     Abstract available
     
     
     
126. ZHANG H, Li S, Zhou R, Dong T, et al
     SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.
     Cancer Lett. 2024;585:216667.
     PubMed     Abstract available
     
     
     
127. ZHOU X, Jia Y, Mao C, Liu S, et al
     Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy.
     Cancer Lett. 2024;580:216481.
     PubMed     Abstract available
     
     
     December 2023
128. YANG Y, Wang J, Wang J, Zhao X, et al
     Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
     Cancer Lett. 2023 Dec 13:216569. doi: 10.1016/j.canlet.2023.216569.
     PubMed     Abstract available
     
     
     
129. MENG Y, Lin W, Wang N, Wei X, et al
     USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.
     Cancer Lett. 2023 Dec 12:216587. doi: 10.1016/j.canlet.2023.216587.
     PubMed     Abstract available
     
     
     
130. XIE Y, Zhang L, Wang L, Chen B, et al
     EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.
     Cancer Lett. 2023;582:216567.
     PubMed     Abstract available
     
     
     
131. YUAN Y, Li Y, Wu X, Bo J, et al
     POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
     Cancer Lett. 2023 Dec 5:216526. doi: 10.1016/j.canlet.2023.216526.
     PubMed     Abstract available
     
     
     
132. KONG R, Wei W, Man Q, Chen L, et al
     Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
     Cancer Lett. 2023;578:216442.
     PubMed     Abstract available
     
     
     November 2023
133. ZHOU Y, Guo Y, Ran M, Shan W, et al
     Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
     Cancer Lett. 2023;577:216425.
     PubMed     Abstract available
     
     
     
134. NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al
     Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
     Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509.
     PubMed     Abstract available
     
     
     
135. CAI S, Zhang B, Huang C, Deng Y, et al
     CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.
     Cancer Lett. 2023;579:216465.
     PubMed     Abstract available
     
     
     
136. LI B, Chen Q, Feng Y, Wei T, et al
     Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per expression and delays NSCLC progression.
     Cancer Lett. 2023;576:216424.
     PubMed     Abstract available
     
     
     October 2023
137. HUA WJ, Yeh H, Lin ZH, Tseng AJ, et al
     Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells.
     Cancer Lett. 2023;578:216458.
     PubMed     Abstract available
     
     
     
138. ZHANG Q, Zheng L, Bai Y, Su C, et al
     ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade.
     Cancer Lett. 2023 Oct 9:216426. doi: 10.1016/j.canlet.2023.216426.
     PubMed     Abstract available
     
     
     September 2023
139. LIU X, Li R, Chen X, Yao J, et al
     SYT7 is a key player in increasing exosome secretion and promoting angiogenesis in non-small-cell lung cancer.
     Cancer Lett. 2023 Sep 27:216400. doi: 10.1016/j.canlet.2023.216400.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum